Drug Trial Radar · NCT01141491
Trivalent Ganglioside Vaccine With Immunological Adjuvant or Immunological Adjuvant Alone in Metastatic Sarcoma Patients Who Are Rendered Disease Free
Last checked: Nov 19, 2026Latest source record: Apr 12, 2017 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
136
Actual
Start
Jun 2010
Primary completion
Sep 2013
Study completion Mar 10, 2017
Sponsor
- Lead sponsor
- MabVax Therapeutics, Inc.Industry
- Sponsor type
- Industry
- First posted
- Jun 10, 2010
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Prevention
- Who can join
- All sexes, from 16 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Sarcoma patients are at high risk for their cancer to recur even when the sarcoma has been removed surgically or treated with radiation or chemotherapy. The patients in the study will be randomized (like flipping a coin) to receive either a vaccine that is combined with an immune system stimulant or the immune system stimulant alone. The immune system stimulant is called OPT-821 and is an immunological booster. The trivalent vaccine is being developed to teach the patient's immune system to recognize 3 types of sugars called GM2, GD2 and GD3 that are found primarily on the surface of sarcoma cells. If the trivalent vaccine can stimulate the patient's immune system to develop antibodies which recognize and target the GM2, GD2 and GM3 sugars, then the patient's antibodies could attack and kill any remaining sarcoma cells potentially preventing the recurrence of sarcoma.
Conditions
- Sarcoma
Interventions
Trivalent ganglioside vaccineBiological
Patients will be given 10 injections of ganglioside vaccine plus adjuvant OPT-821 as a 1.0 ml subcutaneous injection in an outpatient setting at Visit Weeks 1, 2, 3, 8, 16, 28, 40, 52, 68 and 84
OPT-821Biological
Patients will be given 10 injections of adjuvant OPT-821 as a 1.0 ml subcutaneous injection in an outpatient setting at Visit Weeks 1, 2, 3, 8, 16, 28, 40, 52, 68 and 84
Primary outcomes
What the sponsor says the trial is designed to measure.
- Progression Free SurvivalTime frame: 3-years
Locations
13 sites in 1 country. Site status is shown where the registry gives one.
UCLA Medical Center
Los Angeles, California
University of Colorado (Denver)
Denver, Colorado
Winship Cancer Institute at Emory Midtown
Atlanta, Georgia
Northwestern University - Robert H. Lurie Comprehensive Cancer Center
Chicago, Illinois
University of Iowa Hospitals and Clinic
Iowa City, Iowa
Dana Farber Cancer Institute
Boston, Massachusetts
University of Michigan Hospital
Ann Arbor, Michigan
Washington University School of Medicine
St Louis, Missouri
Memorial Sloan-Kettering Cancer Center
New York, New York
Cleveland Clinic
Cleveland, Ohio
Oregon Health & Sciences University
Portland, Oregon
University of Pittsburg Hillman Cancer Center
Pittsburgh, Pennsylvania
Fred Hutchinson Cancer Research Center/Seattle Cancer Care
Seattle, Washington
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.